Država: Novi Zeland
Jezik: engleski
Izvor: Medsafe (Medicines Safety Authority)
Pancuronium bromide 2 mg/mL
AstraZeneca Limited
Pancuronium bromide 2 mg/mL
4 mg/2mL
Solution for injection
Active: Pancuronium bromide 2 mg/mL Excipient: Acetic acid Sodium acetate trihydrate Sodium chloride Sodium hydroxide Water for injection
Polyamp, 2mL, 50 dose units
Prescription
Prescription
Prime European Therapeuticals SpA - Euticals SpA
An adjunct to surgical anaesthesia to induce skeletal muscle relaxation to facilitate operative manipulations. The necessary conditions for intubation can be achieved with Pancuronium alone or following suxamethonium. To promote mechanical ventilation by reducing or eliminating spontaneous breathing effort in intensive care patients.
Package - Contents - Shelf Life: Polyamp, 2mL - 50 dose units - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)
1990-07-04
1 Pancuronium Bromide Data Sheet 280818 NEW ZEALAND DATA SHEET 1. PRODUCT NAME Pancuronium Bromide B.P. 2 mg/mL solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mL sterile solution of pH 3.5-4.2 containing 4 mg pancuronium bromide. Excipients with known effect: sodium chloride, sodium acetate, sodium hydroxide. For the full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, colourless, particle-free solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS An adjunct to surgical anaesthesia to induce skeletal muscle relaxation to facilitate operative manipulations. The necessary conditions for intubation can be achieved with pancuronium alone or following suxamethonium. Pancuronium is also indicated to promote mechanical ventilation by reducing or eliminating spontaneous breathing effort in intensive care patients. 4.2 DOSE AND METHOD OF ADMINISTRATION The following dosage information is a guide only. Pancuronium bromide injection BP is administered intravenously. The dosage should be individualised for each patient as there is wide variation in individual response to muscle relaxants. The potential effect of the anaesthetic or any other concomitant medicine, clinical state of the patient and the anticipated duration of the neuromuscular block must be taken into account when the dosage is determined. It is recommended that a peripheral nerve stimulator be used to monitor response to pancuronium bromide to minimise the risk of overdosage. Since potent inhalation agents or prior administration of suxamethonium enhance the intensity of blockade and duration of action of pancuronium bromide, these factors should be considered when selecting initial and incremental dosage. In heavy or obese patients calculations based on mg/kg may lead to overdosage. For use in one patient on one occasion only. Discard any unused contents of an opened ampoule. 2 Pancuronium Bromide Data Sheet 280818 ADJUNCT TO GENERAL ANAESTHESIA ADULTS AND CHILDREN OLDER THAN 1 MONTH INI Pročitajte cijeli dokument